Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retractable TechnologiesRVP +2.00%35 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates RVP with a GF Score™ of 35/100 and a GF Value™ of $0.75 (Fairly Valued). The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Retractable Technologies ranks worse than 144508.53% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Retractable Technologies was 42.00% per year. The lowest was -74.30% per year. And the median was -2.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Retractable Technologies 3-Year EBITDA Growth Rate Related Terms
RVP vs ZJYL, RGNT, HBIO: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Retractable Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Retractable Technologies 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Retractable Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Retractable Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Retractable Technologies (RVP) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Retractable Technologies and its competitors. According to the industry distribution chart, Retractable Technologies ranks #999999 out of 692 companies in the Medical Devices & Instruments industry.
Is Retractable Technologies' 3-Year EBITDA Growth Rate too high?
Retractable Technologies' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Retractable Technologies ranks #999999 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Retractable Technologies has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Retractable Technologies' 3-Year EBITDA Growth Rate compare to ZJYL and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Retractable Technologies ranks #999999 out of 692 companies for 3-Year EBITDA Growth Rate. This places Retractable Technologies in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Retractable Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Retractable Technologies's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Retractable Technologies stock overvalued right now?
Based on GuruFocus' analysis, Retractable Technologies (RVP) is currently considered Fairly Valued. The stock's GF Value™ is $0.75, compared to a current price of $0.69 — trading 7.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Retractable Technologies' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Retractable Technologies (RVP), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Retractable Technologies (RVP) Overvalued in 2026?
Based on GuruFocus' analysis, Retractable Technologies stock appears to be undervalued.
The current stock price of $0.69 is trading 7.7% below its estimated GF Value™ of $0.75.
GuruFocus considers Retractable Technologies to be Fairly Valued.
Key valuation signals for RVP:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $0.75 vs. price of $0.69 (7.7% below fair value)
No single metric tells the full story. See the RVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.
35GF Score
Get the complete analysis for RVP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVP has been successfully added to your 
